CTLA4 and osteosarcoma: Mice previously treated with α-CTLA-4 and α-PD-L1 mAb and that had previously controlled metastatic osteosarcoma were challenged with 106 K7M2 cells at 100 days post-initial inoculation, a time when neither therapeutic antibody should be present in these mice.